Gentris Joins Personalized Medicine Coalition

Gentris Corporation, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced that the company has joined the Personalized Medicine Coalition (PMC).

The PMC was founded in 2003 by more than 20 leading pharmaceutical, biotechnology, diagnostics and information technology companies, along with major academic centers and governmental agencies. It is an independent, non-profit group dedicated to advancing the understanding and adoption of personalized medicine concepts and products for the ultimate benefit of patients. The Coalition seeks to promote discussion and understanding that will lead to the development of sound public policy on matters that affect the realization of personalized medicine.

“The Coalition brings together leaders from every sector involved in personalized medicine. Together we will educate and explore issues that may require new or revised public policy,” commented Michael Murphy, President and CEO of Gentris. “We are excited to be a part of a group that will have a profound effect on the medical treatments that are currently used, and those still to be discovered.”

Gentris executives are established thought leaders in the field of pharmacogenomics and other important issues surrounding its applications including regulatory, informed consent and patient confidentiality matters, In addition to conducting gene-based clinical trials, Gentris provides consultation on these topics to several participating members of the Pharmacogenomics Working Group. Gentris works with numerous industry groups that are developing guidelines for the adoption of pharmacogenomics in the clinical laboratory setting including the American Association for Clinical Chemistry (AACC). Gentris executives frequently participate in high profile meetings such as the Secretary’s Advisory Committee on Genetics, Health and Society as well as educational forums aimed at helping FDA reviewers understand the possibilities and limitations of clinical pharmacogenomics.

Edward Abrahams, Executive Director of the PMC, sees Gentris as an integral member of the Coalition whose mission it is to advance personalized medicine in the public arena. “Gentris’ leadership in promoting pharmacogenomics can provide invaluable guidance and experience to our members and our mission,” commented Abrahams.

# # #

About Gentris Corporation
Gentris Corporation is a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions. As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market sooner. Gentris is developing diagnostic test kits and validated reference controls that will bring the promise of personalized medicine to physicians and patients, which will enhance patient management, improve patients' response to therapy and revolutionize medicine through pharmacogenomics. For additional information, please visit http://www.gentris.com.

About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC) is an independent, non-profit group that works to advance the understanding and adoption of personalized medicine for the ultimate benefit of patients. Our diverse members work together to educate opinion leaders and the public about the issues that will shape how personalized medicine develops — and how quickly all of us can benefit from it. Please visit the PMC at www.personalizedmedicinecoalition.org .